Topic

Insurance Approval

A collection of 1765 issues

Renewing Zanzalintinib (XL092) Coverage with Humana in Washington: Timeline, Documentation & Appeal Steps

Answer Box: Renewing Zanzalintinib (XL092) Coverage with Humana in Washington Zanzalintinib (XL092) is an investigational drug requiring compassionate use program enrollment through Exelixis, as it's not FDA-approved. Humana typically covers investigational drugs only within clinical trials or approved compassionate use programs. To renew coverage: (1) Confirm continued eligibility

How to Get Strensiq (asfotase alfa) Covered by Cigna in Illinois: Decision Tree, Appeals, and Next Steps

Answer Box: Your Path to Strensiq Coverage in Illinois Cigna requires strict prior authorization for Strensiq (asfotase alfa) for pediatric-onset hypophosphatasia (HPP). You qualify if you have documented perinatal, infantile, or juvenile-onset HPP with low alkaline phosphatase and genetic confirmation. Next steps: (1) Gather diagnostic proof including ALPL mutation testing,

Garadacimab (Andembry) Coverage by Humana in Texas: Formulary Alternatives, Appeals, and Prior Authorization Guide

Quick Answer: Getting Garadacimab (Andembry) Covered by Humana in Texas Garadacimab is not on Humana's 2025 Medicare formulary, requiring a formulary exception request. Texas residents have strong appeal rights through internal reviews (65 days to file) and external reviews via Independent Review Organizations. First step: Have your prescriber

How to Get Duopa Covered by Blue Cross Blue Shield in Pennsylvania: Appeals Guide with Forms and Timelines

Answer Box: Getting Duopa Covered by Blue Cross Blue Shield in Pennsylvania Duopa requires prior authorization from all Pennsylvania Blue Cross Blue Shield plans in 2024. Success requires documenting advanced Parkinson's disease with motor fluctuations, failed oral therapy trials, and surgical candidacy for PEG-J placement. If denied, Pennsylvania&

How to Get Qalsody (Tofersen) Covered by Aetna CVS Health in Ohio: Forms, Appeals, and State Protections

Answer Box: Getting Qalsody (Tofersen) Covered by Aetna CVS Health in Ohio Aetna CVS Health requires prior authorization for Qalsody (tofersen) in Ohio. The fastest path to approval: 1) Confirm SOD1 mutation with genetic testing, 2) Submit complete PA request via Availity portal or fax 1-855-734-9389 with clinical documentation, 3)

How to Get Dojolvi (Triheptanoin) Covered by UnitedHealthcare in Michigan: Complete PA Guide with Appeal Scripts

Answer Box: Getting Dojolvi Covered by UnitedHealthcare in Michigan Dojolvi (triheptanoin) requires prior authorization from UnitedHealthcare for long-chain fatty acid oxidation disorders (LC-FAOD). Key requirements: molecular genetic confirmation of LC-FAOD, prescription from a board-certified medical geneticist, no concurrent MCT products, and dosing ≤35% of daily calories. First step: Download the

How to Get Rinvoq (upadacitinib) Covered by Blue Cross Blue Shield of North Carolina: Prior Authorization Forms, Appeals, and Success Strategies

Answer Box: Getting Rinvoq Covered by BCBS NC Blue Cross Blue Shield of North Carolina requires prior authorization for Rinvoq (upadacitinib) and typically enforces step therapy requirements. Here's your fastest path to approval: 1. Submit PA request using BCBS NC's prior authorization form with documentation of

How to Get Skyrizi (risankizumab) Covered by Aetna CVS Health in Illinois: Complete Guide to Prior Authorization and Appeals

Answer Box: Getting Skyrizi (risankizumab) Covered To get Skyrizi covered by Aetna CVS Health in Illinois: Your doctor must submit a prior authorization showing you meet medical necessity criteria—typically moderate-to-severe disease and documented failure or intolerance to at least one TNF inhibitor (like Humira). The process takes 30-45 days

How Long Does It Take to Get Advate (Octocog Alfa) Approved by UnitedHealthcare in Florida? Complete Timeline Guide

Quick Answer: Advate Approval Timeline for UnitedHealthcare in Florida Standard timeline: 5-14 days for routine prior authorization; 72 hours or less for urgent bleeding episodes. UnitedHealthcare considers Advate a preferred standard half-life factor VIII product, making approval more straightforward than extended half-life alternatives. Your fastest path: Have your hematologist submit

Renewing Vitrakvi (Larotrectinib) Approval with Humana in Washington: Timeline, Documentation & Appeals Guide

Answer Box: Renewing Vitrakvi Coverage with Humana in Washington Vitrakvi (larotrectinib) requires prior authorization renewal with Humana every 3-6 months. Start your renewal 30-45 days before expiration. Submit: updated clinical notes showing continued benefit, recent imaging demonstrating response/stable disease, current liver function tests, and NTRK fusion documentation. If denied,